Topical calcipotriol versus oral psoralen-UVA (PUVA) and topical calcipotriol in the treatment of vitiligo in type IV skin
Keywords:
Vitiligo, topical PUVA, calcipotriolAbstract
Background The treatment of vitiligo is a challenging task. Several therapeutic modalities have been tried till date. Topical calcipotriol alone and in conjunction with PUVA have shown good results in various international studies in the treatment of type I & II vitiliginous skin. Objective Our aim was to evaluate and compare the efficacy of topical calcipotriol alone and in combination with PUVA in the treatment of vitiligo in type IV skin. Patients and methods Sixty patients of vitiligo (26 males & 34 females), aged 12-60 years and involving < 30% of the body surface area were enrolled and randomly divided into two equal groups. Group I patients were treated with twice daily application of topical calcipotriol for six months. In group II patients, in addition to topical calcipotriol, photochemotherapy (PUVA) was advised thrice a week for the same duration. Response was graded according to the degree of repigmentation. Results In group I, only one sixth (16.7 %) of the cases responded and all of them had less than 50% repigmentation whereas in group II, all the patients responded. Seventy percent of the cases in this group showed excellent response (> 75% of repigmentation).  Conclusion We conclude that topical calcipotriol alone has no role in the treatment of vitiligo in type IV skin but when combined with PUVA leads to an excellent response in greater than two third of the patients.ÂReferences
Zettinig G, Tanew SA, Fishcher G et al. Autoimmune diseases in vitiligo: do antinuclear antibodies decrease thyroid volume? Clin Exp Immunol 2003; 131: 347-54.
Kakourou T, Kanaka-Gantenbein C, Papadopoulou A et al. Increased prevalence of chronic autoimmune (Hashimoto’s) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol 2005; 53: 220-3.
Koranue RV, Sachdeva KG. Vitiligo. Int J Dermatol 1988; 27: 676-81.
Howitz J, Brodthagen H, Schwartz M et al. Prevalence of vitiligo. Arch Dermatol 1977; 113: 47-52.
Noor SM, Khurshid K, Mehmood T, Haroon TS. Quality of life in vitiligo patients. J Pak Assoc Dermatol 2004; 14: 55-8.
Baysal V, Yildirim M, Erel A, Kesici D. Is the combination of calcipotriol and PUVA effective in vitiligo? J Eur Acad Dermatol Venereol 2003; 17: 299-302.
Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol 2001; 145: 476-9.
Kumaran M, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 2006; 20: 269-73.
Ermis O, Alpsoy E, Centin L, Yilmaz E. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo –controlled, double-blind study. Br J Dermatol 2001; 145: 472-5.
Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology 1998; 197: 167-70.
Parsad D, Kanwar AJ, Kumar B. Psoralen-ultraviolet A vs narrow-band ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol 2006; 20: 175-7.
Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38: 647-66.
Bertolini DL, Avaujo PR, Silva RN. Immunomodulatory effects of vitamin D analogue KH 1060 on an experimental skin transplantation model. Transplant Proc 1999; 31: 2998-9.
Schallreuter KU, Pittelkow MR. Defective calcium uptake in keratinocyte cell culture from vitiliginous skin. Arch Dermatol Res 1988; 280: 137-9.
Schallreuter KU, Pittelkow MR, Swanson NN. Defective calcium transport in vitiliginous melanocytes. Arch Dermatol Res 1996; 228: 11-3.
Milde P, Hauser U, Simon T et al. Expression of 1, 25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol 1991; 97: 230-9.
Nordlund J, Abdel-Malek ZA, Boissy RE et al. Pigment cell biology: an historical review. J Invest Dermatol 1989; 92 (Suppl. 4): 53-9S.
Reichrath J, Muller SM, Kerber A et al. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 1997; 36: 19-28.
